Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saiz, A.
Right arrow Articles by Graus, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saiz, A.
Right arrow Articles by Graus, F.
NEUROLOGY 2004;62:282-284
© 2004 American Academy of Neurology
Brief Communications

Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS

A. Saiz, MD, Y. Blanco, MD, E. Carreras, MD, J. Berenguer, MD, M. Rovira, MD, T. Pujol, MD, P. Marín, MD, T. Arbizu, MD and F. Graus, MD

From the Services of Neurology (Drs. Saiz, Blanco, and Graus), Bone Marrow Transplantation Unit, Hematology (Drs. Carreras and Rovira), Radiology (Drs. Berenguer and Pujol), and Blood Bank and Cryopreservation Unit (Dr. Marin), Hospital Clínic, Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; and Service of Neurology (Dr. Arbizu), Unidad de Esclerosis Múltiple, C. S. U. de Bellvitge, L'Hospitalet, Barcelona, Spain.

Address correspondence and reprint requests to Dr. Francesc Graus, Service of Neurology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain; e-mail: graus{at}medicina.ub.es

The authors report the outcome of 14 patients with severe multiple sclerosis treated with autologous hematopoietic stem cell transplantation (AHSCT) after a median follow-up period of 3 years. The 3-year actuarial probability of progression-free survival was 85.7% and that of disease activity-free survival was 46.4%. On MRI, no T1-enhanced lesions were detected after AHSCT. The mean change in T2 lesion volume from baseline to the third year was -20.2% and that of the corpus callosum area was -12.7%; 50% of this reduction was seen during the first year.

Received March 19, 2003. Accepted in final form October 11, 2003.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
P. Rieckmann, A. Traboulsee, V. Devonshire, and J. Oger
Review: Escalating immunotherapy of multiple sclerosis
Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 181 - 192.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
T Mondria, C H J Lamers, P A W t. Boekhorst, J W Gratama, and R Q Hintzen
Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1013 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Vermeulen and M H J van Oers
Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation
J. Neurol. Neurosurg. Psychiatry, October 1, 2007; 78(10): 1154 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
M.A. Rocca, T. Mondria, P. Valsasina, M.P. Sormani, Z.H. Flach, P.A. Te Boekhorst, G. Comi, R.Q. Hintzen, and M. Filippi
A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1659 - 1661.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Denier, J. -H. Bourhis, C. Lacroix, S. Koscielny, J. Bosq, R. Sigal, G. Said, and D. Adams
Spectrum and prognosis of neurologic complications after hematopoietic transplantation
Neurology, December 12, 2006; 67(11): 1990 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R Saccardi, T Kozak, C Bocelli-Tyndall, A Fassas, A Kazis, E Havrdova, E Carreras, A Saiz, B Lowenberg, P A. te Boekhorst, et al.
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
Multiple Sclerosis, November 1, 2006; 12(6): 814 - 823.
[Abstract] [PDF]

Home page
 Mult SclerHome page
M Daumer, L M Griffith, W Meister, R A Nash, and J S Wolinsky
Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Multiple Sclerosis, April 1, 2006; 12(2): 174 - 179.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J P A Samijn, P A W te Boekhorst, T Mondria, P A van Doorn, H Z Flach, F G A van der Meche, J Cornelissen, W C Hop, B Lowenberg, and R Q Hintzen
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 46 - 50.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. S. Freedman and H. L. Atkins
Suppressing immunity in advancing MS: Too much too late, or too late for much?
Neurology, January 27, 2004; 62(2): 168 - 169.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.